HealthInvest Partners’s BridgeBio Pharma BBIO Stock Holding History

HealthInvest Partners’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.29M	Buy	124,707 +13,344	+12%	+$935K	2.5%	18
2026 Q1	$11.9M	Sell	111,363 -29,933	-21%	-$2.17M	3.84%	6
2025 Q4	$10.8M	Sell	141,296 -33,426	-19%	-$2.19M	3.45%	8
2025 Q3	$9.08M	Buy	174,722 +9,242	+6%	+$451K	3.57%	7
2025 Q2	$7.15M	Buy	165,480 +14,132	+9%	+$514K	3.06%	12
2025 Q1	$5.23M	Buy	151,348 +48,316	+47%	+$1.63M	2.31%	16
2024 Q4	$2.81M	Buy	103,032 +49,600	+93%	+$1.28M	1.34%	23
2024 Q3	$1.36M	Hold	53,432	–	–	0.64%	31
2024 Q2	$1.35M	Buy	53,432 +15,591	+41%	+$426K	0.83%	29
2024 Q1	$1.17M	Buy	37,841 +13,856	+58%	+$471K	0.71%	33
2023 Q4	$968K	Buy	+23,985	New	+$720K	0.76%	29
2022 Q4	$6.76K	Buy	+887	New	+$8.49K	0.01%	45

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

HealthInvest Partners's BBIO Position: Q2 2026 in Review

HealthInvest Partners increased its BridgeBio Pharma (BBIO) stake by 12% in Q2 2026, buying an estimated $935K and bringing the position to 124,707 shares worth $9.29M. The position accounts for 2.5% of the portfolio, ranked #18.

HealthInvest Partners first reported a position in BBIO in Q4 2022 and has held it in 12 quarters since. The position peaked at $11.9M in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

HealthInvest Partners held 124,707 shares of BridgeBio Pharma worth $9.29M as of Q2 2026.
HealthInvest Partners bought 13,344 BridgeBio Pharma shares in Q2 2026, an estimated $935K.
BridgeBio Pharma made up 2.5% of HealthInvest Partners's portfolio in Q2 2026, its #18 holding.
HealthInvest Partners first reported a position in BridgeBio Pharma in Q4 2022 and has held it in 12 quarters since.
HealthInvest Partners's BridgeBio Pharma position peaked at $11.9M in Q1 2026.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on HealthInvest Partners's 13F filing for Q2 2026, filed 24 Jul 2026.